Connecting you to perspectives from around the world
Playlist
In Focus: The Return of Inflation
Key inflation gauge jumps to 3-year high in latest sign of affordability challenges
WASHINGTON (AP) — The Federal Reserve’s preferred inflation gauge rose to a new three-year high in May as gas prices peaked, a sign rising costs could pose political problems for President Trump as midterm elections near. The Commerce Department said Thursday that consumer prices rose 4.1% in May from a…
Read more
ASEAN’s Next Inflation Test Is Moving From Oil Into Food
A stronger El Niño would arrive at the worst possible time, just as higher input costs begin to reach consumers. Takeaways Higher oil and fertilizer prices are now entering the food-cost pipeline, with the main CPI impact still ahead rather than behind. A stronger El Niño would arrive at the…
Read more
Inflation is eroding cash returns. Here’s where to park your savings.
Personal Finance Inflation is eroding cash returns. Here’s where to park your savings Personal Finance Inflation is eroding cash returns. Here’s where to park your savings Inflation is eroding cash returns. Here’s where to park your savings Personal Finance Inflation is eroding cash returns. Here’s where to park your savings…
Read more
Beyond Logistics: Can the Land Bridge Become the New Growth Engine for Thailand?
When Iran closed the Strait of Hormuz in early 2026, the disruption was immediate and global. Oil prices spiked. Shipping lines scrambled for alternatives. And in Southeast Asia, policymakers were forced to confront an uncomfortable question they had long deferred: what happens when the world’s maritime chokepoints fail? The Hormuz…
Read more
Sanofi to buy early-stage vaccine maker Vicebio for $1.15B upfront
Sanofi will acquire the London-based vaccine startup Vicebio for $1.15 billion upfront and as much as $450 million in future payments, the companies said Tuesday. The deal marks Sanofi’s fourth acquisition of the year, following the recently completed $9 billion purchase of commercial-stage drugmaker Blueprint Medicines, an Alzheimer’s pipeline expansion…
Read more
How a tailored ALS drug could help broaden rare disease therapies
In 2020, Jaci Hermstad died at age 26 from a rare and aggressive form of ALS. But her story didn’t end there. A drug that was created just for her, called Jacifusen, has since been given to others with mutations in the FUS gene, what’s known as FUS-ALS. The results in…
Read more
After long saga, 23andMe’s deal with Anne Wojcicki’s nonprofit finally closes
At long last, Anne Wojcicki has officially bought 23andMe. The co-founder and former CEO’s nonprofit, TTAM Research Institute, on Monday said it had completed the acquisition of 23andMe’s consumer genetics business and its research unit. In June, Wojcicki’s TTAM won a bid to acquire 23andMe for $305 million as part…
Read more
FDA Pathways Offer Faster Track for Oncology Drug Development
For biotech companies advancing oncology therapies, regulatory speed can be critical to achieving key milestones and getting new therapies to patients faster. In a recent interview, Josh Taylor, PhD, senior director of regulatory affairs at Allucent, discussed how biotech companies can leverage the FDA’s expedited programs—Fast Track, Breakthrough Therapy, Accelerated…
Read more
10 clinical trials to watch the rest of 2025
Expected readouts in obesity, lung cancer and atopic dermatitis headline a series of study results that could give the biotechnology sector a boost in another down year.
Read more
Cancer drugmaker LaNova to sell to China’s Sino Biopharm
Sino Biopharmaceuticals plans to pay up to $950.9 million to acquire LaNova Medicines, which previously licensed drugs to Merck and AstraZeneca.
Read more
Merck to buy Verona and its lung drug in $10B deal
The New Jersey-based pharma has inked one of the biggest deals of the year in pursuit of a promising new way to treat COPD.
Read more